N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity By Ogkologos - January 23, 2026 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the I-PREDICT study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New on NCI’s Websites for November 2021 November 5, 2021 FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma April 1, 2026 FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Load more HOT NEWS Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV...
